NCT05372991 - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

January 18, 2023

Study Completion Date

January 20, 2023

Conditions

Myopia, Progressive

Interventions

DRUG

CBT-009

This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

DRUG

Vehicle

This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

DRUG

Atropine Sulfate

This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

Trial Locations (1)

USC, Brisbane